 This study investigated the preventative effects of betalinic acid, BA, on streptozotocinicateinamide, STZ, induced diabetic nephropathy in male mice. The results showed that BA had a protective effect against diabetic nephropathy, as it significantly reduced albumin, blood urea nitrogen, BUN, and creatinine levels in the plasma, as well as improving renal histological changes. Additionally, BA also demonstrated a similar effect to metformin, which is currently used to treat type 2 diabetes. This article was authored by Opchroma Hangerper, Ali Opbar Origin, Lysodac Crisandi, and others.